Recent advances in targeted drug delivery systems for multiple myeloma.

Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4995 (Electronic) Linking ISSN: 01683659 NLM ISO Abbreviation: J Control Release Subsets: MEDLINE

Original Publication: Amsterdam : Elsevier Science Publishers, 1984-

Multiple Myeloma*/drug therapy ; Drug Delivery Systems* ; Antineoplastic Agents*/administration & dosage ; Antineoplastic Agents*/therapeutic use; Humans ; Animals ; Nanoparticles ; Immunotherapy/methods

Despite significant therapeutic advances, multiple myeloma (MM) remains a challenging, incurable, hematological malignancy. The efficacy of traditional chemotherapy and currently available anti-MM agents is in part limited by their adverse effects, which restrict their therapeutic potential. Nanotherapeutics is an emerging field of cancer therapy that can overcome the biological and chemical barriers of existing anticancer drugs. This review presents an overview of recent advancements in nanoparticle- and immunotherapy-based drug delivery systems for MM treatment. It further delves into the targeting strategies, mechanism of controlled drug release, and challenges associated with the development of drug delivery systems for the treatment of MM.
(Copyright © 2024 Elsevier B.V. All rights reserved.)

J Immunol Methods. 2019 May;468:55-60. (PMID: 30880262)
Nanomedicine (Lond). 2014 Mar;9(3):487-99. (PMID: 24746192)
J Hematol Oncol. 2020 Sep 17;13(1):125. (PMID: 32943087)
Blood. 2014 May 15;123(20):3128-38. (PMID: 24569262)
Nat Rev Clin Oncol. 2017 Jul;14(7):417-433. (PMID: 28117417)
Cancer Treat Rev. 2017 Apr;55:190-199. (PMID: 28431262)
J Control Release. 2020 Apr 10;320:421-430. (PMID: 32027936)
Clin Cancer Res. 2022 May 2;28(9):1759-1764. (PMID: 35046063)
Biomed Microdevices. 2004 Jun;6(2):113-6. (PMID: 15320632)
Mol Cancer Ther. 2016 Jul;15(7):1452-9. (PMID: 27196779)
Cells. 2020 Jan 09;9(1):. (PMID: 31936617)
J Clin Med. 2021 Apr 23;10(9):. (PMID: 33922721)
Acta Biomater. 2018 Oct 15;80:288-295. (PMID: 30240956)
Annu Rev Pathol. 2011;6:249-74. (PMID: 21261519)
J Cell Mol Med. 2014 Jun;18(6):947-61. (PMID: 24712303)
Leukemia. 2016 Apr;30(4):987-91. (PMID: 26242462)
Nat Rev Cancer. 2002 Dec;2(12):927-37. (PMID: 12459731)
Biomolecules. 2020 Oct 09;10(10):. (PMID: 33050144)
Adv Mater. 2019 Nov;31(46):e1904742. (PMID: 31560141)
J Cell Mol Med. 2018 Dec;22(12):5978-5990. (PMID: 30353654)
Mayo Clin Proc. 2004 Jul;79(7):899-903. (PMID: 15244387)
Lancet Haematol. 2021 Nov;8(11):e794-e807. (PMID: 34529955)
Biochem Pharmacol. 1999 Apr 1;57(7):727-41. (PMID: 10075079)
Leuk Lymphoma. 2023 Feb;64(2):283-291. (PMID: 36308022)
Int J Nanomedicine. 2020 Nov 25;15:9447-9467. (PMID: 33268987)
Leukemia. 2009 Jan;23(1):10-24. (PMID: 18843284)
J Control Release. 2021 Apr 10;332:127-147. (PMID: 33609621)
Immunol Res. 2014 Aug;59(1-3):203-10. (PMID: 24906530)
Blood. 2004 Aug 1;104(3):607-18. (PMID: 15090448)
J Pers Med. 2021 Jun 18;11(6):. (PMID: 34207137)
Int J Mol Sci. 2022 Feb 06;23(3):. (PMID: 35163755)
Drugs. 2020 Oct;80(15):1607-1613. (PMID: 32936437)
Drug Deliv Transl Res. 2023 Apr;13(4):915-923. (PMID: 36592287)
Blood Cancer J. 2023 Apr 7;13(1):48. (PMID: 37029121)
Blood. 2018 Feb 22;131(8):855-863. (PMID: 29203585)
Avicenna J Med Biotechnol. 2019 Jan-Mar;11(1):3-23. (PMID: 30800238)
ACS Appl Mater Interfaces. 2023 Feb 8;15(5):6312-6325. (PMID: 36701696)
Biochim Biophys Acta. 2000 Jun 1;1466(1-2):205-20. (PMID: 10825443)
J Hematol Oncol. 2017 Jan 11;10(1):13. (PMID: 28077160)
Blood. 2008 Mar 15;111(6):2962-72. (PMID: 18332230)
J Control Release. 2015 May 10;205:144-54. (PMID: 25596560)
Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5556s-5563s. (PMID: 17875789)
Drugs. 2017 Apr;77(5):505-520. (PMID: 28205024)
Biomed Pharmacother. 2020 Feb;122:109712. (PMID: 31918281)
J Am Coll Cardiol. 2010 Jan 19;55(3):213-20. (PMID: 20117401)
Lancet Haematol. 2023 Oct;10(10):e801-e812. (PMID: 37793771)
Nanoscale. 2019 Mar 7;11(10):4414-4427. (PMID: 30801591)
Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10287-92. (PMID: 24982170)
J Pers Med. 2021 Apr 23;11(5):. (PMID: 33922567)
Nanomaterials (Basel). 2022 Jun 04;12(11):. (PMID: 35683777)
Dtsch Arztebl Int. 2016 Jul 11;113(27-28):470-6. (PMID: 27476706)
AAPS PharmSciTech. 2014 Dec;15(6):1527-34. (PMID: 25047256)
Nat Rev Mater. 2021;6(12):1078-1094. (PMID: 34394960)
Jpn J Cancer Res. 1998 Mar;89(3):307-14. (PMID: 9600125)
Ther Adv Med Oncol. 2022 Apr 11;14:17588359221087555. (PMID: 35432603)
Drug Metab Dispos. 2013 Jan;41(1):230-7. (PMID: 23118326)
Haematologica. 2020 Jul 23;105(10):2358-2367. (PMID: 33054076)
Nat Rev Drug Discov. 2008 Mar;7(3):255-70. (PMID: 18219308)
J Support Oncol. 2003 Sep-Oct;1(3):194-205. (PMID: 15334875)
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16090-5. (PMID: 16243973)
CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
Int J Mol Sci. 2022 Jan 31;23(3):. (PMID: 35163567)
J Control Release. 2019 Oct;311-312:190-200. (PMID: 31473250)
Nat Commun. 2018 Apr 12;9(1):1410. (PMID: 29650952)
Cancers (Basel). 2021 Jan 09;13(2):. (PMID: 33435306)
Int J Pharm X. 2019 Mar 23;1:100011. (PMID: 31517276)
Am Health Drug Benefits. 2016 Mar;9(Spec Feature):102-5. (PMID: 27668055)
Anticancer Drugs. 2003 Sep;14(8):617-24. (PMID: 14501383)
Circulation. 2004 Jun 29;109(25):3122-31. (PMID: 15226229)
Int J Mol Sci. 2023 Aug 29;24(17):. (PMID: 37686170)
Leukemia. 2020 Sep;34(9):2430-2440. (PMID: 32094461)
Neoplasia. 2019 Aug;21(8):777-787. (PMID: 31247457)
J Clin Oncol. 2020 Jun 10;38(17):1928-1937. (PMID: 32298201)
J Clin Med. 2020 Sep 27;9(10):. (PMID: 32992506)
Curr Cancer Drug Targets. 2011 Mar;11(3):239-53. (PMID: 21247388)
Clin Pharmacol Drug Dev. 2019 Apr;8(3):346-354. (PMID: 29746728)
Front Genet. 2021 Jun 07;12:640954. (PMID: 34163520)
Cancer Cell. 2008 Feb;13(2):167-80. (PMID: 18242516)
Cancers (Basel). 2020 Oct 27;12(11):. (PMID: 33120945)
Clin Cancer Res. 2013 Jun 1;19(11):3019-31. (PMID: 23584492)
Small. 2023 Oct;19(40):e2301748. (PMID: 37282762)
Cancers (Basel). 2020 Apr 10;12(4):. (PMID: 32290285)
Int J Mol Sci. 2019 Oct 25;20(21):. (PMID: 31731563)
Clin Lymphoma Myeloma Leuk. 2018 May;18(5):335-345. (PMID: 29610030)
J Biomed Nanotechnol. 2014 Feb;10(2):336-44. (PMID: 24738341)
Am J Hematol. 1991 Mar;36(3):171-5. (PMID: 1996557)
Med Sci Monit. 2019 Oct 10;25:7605-7616. (PMID: 31599230)
Front Immunol. 2020 Oct 12;11:567365. (PMID: 33154748)
Cancers (Basel). 2020 Jan 22;12(2):. (PMID: 31979059)
Cancer Med. 2020 Sep;9(18):6726-6738. (PMID: 32717133)
Lancet. 2014 Sep 27;384(9949):1187-95. (PMID: 24930728)
Cancer Manag Res. 2017 Mar 02;9:51-63. (PMID: 28280389)
Drugs. 2022 Nov;82(16):1613-1619. (PMID: 36352205)
Acc Chem Res. 2019 Sep 17;52(9):2445-2461. (PMID: 31424909)
Nanoscale. 2021 Jun 28;13(24):10748-10764. (PMID: 34132312)
Front Immunol. 2018 Nov 19;9:2553. (PMID: 30524421)
Nat Rev Cancer. 2011 Apr;11(4):254-67. (PMID: 21390059)
Lancet. 2019 Jul 6;394(10192):29-38. (PMID: 31171419)
Blood. 2011 Nov 3;118(18):4771-9. (PMID: 21860026)
Antib Ther. 2018 Jun 24;1(1):7-12. (PMID: 33928217)
Bioorg Med Chem Lett. 2019 Oct 1;29(19):126633. (PMID: 31474482)
Small Methods. 2024 Jan;8(1):e2300843. (PMID: 37800985)
J Pharmacol Exp Ther. 2015 Nov;355(2):168-73. (PMID: 26311812)
Cancer Sci. 2011 Mar;102(3):501-8. (PMID: 21205077)
Clin Cancer Res. 2021 Apr 1;27(7):1974-1986. (PMID: 33355244)
Drug Res (Stuttg). 2019 Feb;69(3):130-135. (PMID: 30452078)
J Hematol Oncol. 2020 Nov 2;13(1):145. (PMID: 33138841)
J Med Chem. 2014 Jun 26;57(12):5282-92. (PMID: 24897555)
Mod Pathol. 2001 Oct;14(10):1052-8. (PMID: 11598177)
Drugs. 1997;54 Suppl 4:1-7. (PMID: 9361955)
Biomaterials. 2023 Jan;292:121913. (PMID: 36442437)
Sci Rep. 2015 Dec 01;5:17579. (PMID: 26620594)
Cancers (Basel). 2020 Dec 15;12(12):. (PMID: 33333816)
Nanoscale Res Lett. 2018 Nov 22;13(1):373. (PMID: 30467726)
Biomaterials. 2009 May;30(13):2606-13. (PMID: 19162320)
Front Immunol. 2020 Jun 19;11:1155. (PMID: 32636838)
Cancer. 2002 Nov 15;95(10):2160-8. (PMID: 12412170)
Chem Rev. 2021 Feb 10;121(3):1746-1803. (PMID: 33445874)
Asian Pac J Cancer Prev. 2014;15(2):517-35. (PMID: 24568455)
ACS Nano. 2020 Apr 28;14(4):4255-4264. (PMID: 32223222)
J Control Release. 2018 Oct 10;287:194-215. (PMID: 30165140)
PLoS One. 2013;8(2):e57641. (PMID: 23437401)
Commun Biol. 2020 Dec 17;3(1):781. (PMID: 33335255)
Cancers (Basel). 2020 Sep 21;12(9):. (PMID: 32967380)
Blood. 2009 Jul 16;114(3):619-29. (PMID: 19443661)
Beilstein J Nanotechnol. 2020 Feb 14;11:338-353. (PMID: 32117671)
Oncotarget. 2018 Dec 28;9(102):37700-37714. (PMID: 30701025)
J Control Release. 2018 Jan 28;270:158-176. (PMID: 29196043)
J Microencapsul. 2021 May;38(3):192-202. (PMID: 33530812)
Methods Mol Biol. 2010;605:189-203. (PMID: 20072882)
Onco Targets Ther. 2014 Sep 29;7:1793-800. (PMID: 25302026)
Biomacromolecules. 2019 Feb 11;20(2):916-926. (PMID: 30571914)
J Drug Target. 2003 Jul;11(6):355-63. (PMID: 14668056)
Nat Nanotechnol. 2023 Feb;18(2):184-192. (PMID: 36702954)
Adv Drug Deliv Rev. 2007 Aug 10;59(8):748-58. (PMID: 17659804)
Cancers (Basel). 2019 Feb 20;11(2):. (PMID: 30791634)
Nanomedicine. 2013 Jan;9(1):1-14. (PMID: 22684017)
Br J Cancer. 2008 Jun 17;98(12):1966-74. (PMID: 18521088)
N Engl J Med. 1971 Nov 18;285(21):1182-6. (PMID: 4938153)
Front Pharmacol. 2021 Apr 19;12:636892. (PMID: 33953675)
Cancer Manag Res. 2020 Aug 06;12:6969-6976. (PMID: 32848460)
Sci Rep. 2022 Oct 26;12(1):17961. (PMID: 36289430)
Biomacromolecules. 2020 Jun 8;21(6):2049-2059. (PMID: 32338875)
Adv Sci (Weinh). 2023 Jul;10(21):e2301377. (PMID: 37171801)
Clin Pharmacokinet. 2021 Aug;60(8):957-969. (PMID: 33928519)
Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):372-380. (PMID: 30930134)
J Control Release. 2021 Sep 10;337:571-588. (PMID: 34364920)
Adv Enzyme Regul. 2001;41:189-207. (PMID: 11384745)
Int J Cancer. 2014 Jan 1;134(1):218-23. (PMID: 23775066)
Pharmaceutics. 2021 Feb 18;13(2):. (PMID: 33670464)
Inflamm Regen. 2020 Mar 30;40:4. (PMID: 32256871)
Clin Cancer Res. 2004 Oct 1;10(19):6606-11. (PMID: 15475450)
Drugs. 2018 Jan;78(1):19-37. (PMID: 29188449)
Clin Cancer Res. 2009 Jun 15;15(12):4028-37. (PMID: 19509164)
Blood Adv. 2017 Feb 27;1(7):449-454. (PMID: 29296960)
Am J Transl Res. 2011 Feb;3(2):166-79. (PMID: 21416059)
Nanoscale Res Lett. 2022 Aug 5;17(1):72. (PMID: 35930196)
Cell Immunol. 2013 Jul-Aug;284(1-2):129-38. (PMID: 23973876)
Nanomedicine (Lond). 2014 Jan;9(1):45-60. (PMID: 23534833)
N Engl J Med. 2019 Aug 22;381(8):727-738. (PMID: 31433920)
Leukemia. 2021 Jan;35(1):255-258. (PMID: 32317775)
J Hematol Oncol. 2019 Sep 10;12(1):94. (PMID: 31500657)
Int J Pharm. 2023 Aug 25;643:123241. (PMID: 37479101)
Nat Rev Drug Discov. 2003 May;2(5):347-60. (PMID: 12750738)
Int J Nanomedicine. 2015 Apr 30;10:3275-89. (PMID: 25995634)
Nat Rev Clin Oncol. 2010 Nov;7(11):653-64. (PMID: 20838415)
Bioeng Transl Med. 2019 Sep 05;4(3):e10143. (PMID: 31572799)
Int Immunopharmacol. 2020 Jul;84:106516. (PMID: 32334387)
Oncology. 2005;69 Suppl 3:4-10. (PMID: 16301830)
Br J Haematol. 2011 Mar;152(5):593-9. (PMID: 21241279)
Clin Cancer Res. 2019 Jan 15;25(2):478-486. (PMID: 30279233)
Leukemia. 2020 Jan;34(1):210-223. (PMID: 31427721)
Eur J Haematol. 2017 Jun;98(6):529-541. (PMID: 28208215)
ACS Nano. 2013 Apr 23;7(4):2935-47. (PMID: 23421406)
Pharmaceutics. 2018 Sep 10;10(3):. (PMID: 30201882)
Cancer Res Treat. 2015 Oct;47(4):607-15. (PMID: 25715763)
Acta Pharm Sin B. 2023 Apr;13(4):1358-1370. (PMID: 37139427)
Lancet Oncol. 2020 Feb;21(2):207-221. (PMID: 31859245)
ACS Appl Mater Interfaces. 2018 Apr 25;10(16):13274-13282. (PMID: 29595244)
N Engl J Med. 2011 Mar 17;364(11):1046-60. (PMID: 21410373)
Adv Drug Deliv Rev. 2011 Aug 14;63(9):789-808. (PMID: 21447363)
Int J Nanomedicine. 2013;8:1439-49. (PMID: 23610522)
Biochem Pharmacol. 2010 May 1;79(9):1281-90. (PMID: 20067771)
Blood Cancer J. 2012 Apr;2(4):e64. (PMID: 22829966)
J Biomed Mater Res B Appl Biomater. 2018 Apr;106(3):1165-1173. (PMID: 28556562)
Clin Pharmacokinet. 2004;43(5):311-27. (PMID: 15080764)
Hemasphere. 2020 Aug 27;4(5):e463. (PMID: 32923984)
J Clin Oncol. 2021 Mar 1;39(7):757-767. (PMID: 33296242)
Nature. 2011 Dec 14;480(7377):S38-9. (PMID: 22169799)
Nat Commun. 2020 Nov 27;11(1):6037. (PMID: 33247158)
Clin Cancer Res. 2013 Sep 1;19(17):4559-63. (PMID: 23775332)
Int J Nanomedicine. 2018 Nov 29;13:8105-8118. (PMID: 30555229)
Drugs. 2016 Mar;76(3):405-11. (PMID: 26846321)
Otolaryngol Clin North Am. 2010 Aug;43(4):753-68. (PMID: 20599080)
Int J Hematol. 2015 Jun;101(6):578-84. (PMID: 25749662)
PLoS One. 2012;7(12):e51661. (PMID: 23251606)
J Clin Oncol. 2007 Sep 1;25(25):3892-901. (PMID: 17679727)
Eur J Pharm Biopharm. 2012 Feb;80(2):241-6. (PMID: 21888972)
Int J Hematol. 2008 Sep;88(2):219-222. (PMID: 18633693)
J Oncol Pharm Pract. 2019 Apr;25(3):613-622. (PMID: 30060709)
J Control Release. 2015 Feb 28;200:158-66. (PMID: 25550153)
Proc Natl Acad Sci U S A. 2023 Jun 20;120(25):e2215711120. (PMID: 37310997)
Chem Rec. 2019 Feb;19(2-3):502-522. (PMID: 30156367)
Transl Oncol. 2022 Apr;18:101374. (PMID: 35196605)
Br J Haematol. 2007 Aug;138(3):396-7. (PMID: 17561972)
Int J Mol Sci. 2017 Jan 10;18(1):. (PMID: 28075405)

P30 CA036727 United States CA NCI NIH HHS; R01 CA258621 United States CA NCI NIH HHS

Keywords: Antibody drug conjugates; Multiple myeloma; Nanoparticles; Targeted drug delivery system

0 (Antineoplastic Agents)

Date Created: 20241009 Date Completed: 20241202 Latest Revision: 20241209

20241210

PMC11611669

10.1016/j.jconrel.2024.10.003

39384153